Lee Ainslie Verona Pharma PLC Transaction History
Maverick Capital LTD
- $5.17 Billion
- Q4 2024
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Verona Pharma PLC stock. As of the latest transaction made, Maverick Capital LTD holds 3,128,516 shares of VRNA stock, worth $230 Million. This represents 2.81% of its overall portfolio holdings.
Number of Shares
3,128,516
Previous 4,215,973
25.79%
Holding current value
$230 Million
Previous $121 Million
19.78%
% of portfolio
2.81%
Previous 2.52%
Shares
5 transactions
Others Institutions Holding VRNA
# of Institutions
229Shares Held
68.1MCall Options Held
1.4MPut Options Held
299K-
Perceptive Advisors LLC New York, NY6.39MShares$470 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$410 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$249 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$230 Million2.79% of portfolio
-
Abingworth LLP London, X02.46MShares$181 Million21.3% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $4.48B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...